Cargando…
Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
BACKGROUND/AIMS: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. METHODS: We prospectively enrolled 55 consecutive patients with ACS: 25...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604606/ https://www.ncbi.nlm.nih.gov/pubmed/23525523 http://dx.doi.org/10.3904/kjim.2013.28.2.165 |
_version_ | 1782263768386895872 |
---|---|
author | Guzel, Savas Serin, Ozden Guzel, Eda Celik Buyuk, Banu Yılmaz, Güzin Güvenen, Guvenc |
author_facet | Guzel, Savas Serin, Ozden Guzel, Eda Celik Buyuk, Banu Yılmaz, Güzin Güvenen, Guvenc |
author_sort | Guzel, Savas |
collection | PubMed |
description | BACKGROUND/AIMS: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. METHODS: We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. RESULTS: Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). CONCLUSIONS: Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS. |
format | Online Article Text |
id | pubmed-3604606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-36046062013-03-22 Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction Guzel, Savas Serin, Ozden Guzel, Eda Celik Buyuk, Banu Yılmaz, Güzin Güvenen, Guvenc Korean J Intern Med Original Article BACKGROUND/AIMS: Acute coronary syndrome (ACS) is characterized by increased inflammatory processes and endothelial activation. We investigated the association between ACS and inflammatory mediators and matrix-degrading enzymes. METHODS: We prospectively enrolled 55 consecutive patients with ACS: 25 with unstable angina (UA) and 30 with non-ST elevated myocardial infarction (NSTEMI). For comparison, 25 age- and sex-matched subjects with no significant coronary artery stenosis were included as the control group. Peripheral serum levels of interleukin (IL)-33, matrix metalloproteinase (MMP)-9, tissue inhibitor of MMP-1, and C-reactive protein (CRP) were measured on admission, and at 12, 24, 48, and 72 hours after the initial evaluation. RESULTS: Compared to serum levels in the control group, serum levels of IL-33 decreased in the NSTEMI group (p < 0.05), and levels of MMP-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 increased in the UA group (p < 0.01, p < 0.05, respectively) and NSTEMI group (p < 0.05, p < 0.05, respectively). IL-33 levels were significantly lower on admission than at 12 hours after the initial evaluation (p < 0.05). IL-33 levels were negatively correlated with MMP-9 levels (r = -0.461, p < 0.05) and CRP levels (r = -0.441, p < 0.05). CONCLUSIONS: Elevated levels of MMP-9, TIMP-1, and decreased levels of IL-33 play a role in the development and progression of ACS. The Korean Association of Internal Medicine 2013-03 2013-02-27 /pmc/articles/PMC3604606/ /pubmed/23525523 http://dx.doi.org/10.3904/kjim.2013.28.2.165 Text en Copyright © 2013 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Guzel, Savas Serin, Ozden Guzel, Eda Celik Buyuk, Banu Yılmaz, Güzin Güvenen, Guvenc Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
title | Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
title_full | Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
title_fullStr | Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
title_full_unstemmed | Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
title_short | Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
title_sort | interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3604606/ https://www.ncbi.nlm.nih.gov/pubmed/23525523 http://dx.doi.org/10.3904/kjim.2013.28.2.165 |
work_keys_str_mv | AT guzelsavas interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction AT serinozden interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction AT guzeledacelik interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction AT buyukbanu interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction AT yılmazguzin interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction AT guvenenguvenc interleukin33matrixmetalloproteinase9andtissueınhibitorofmatrixmetalloproteinase1inmyocardialinfarction |